# Hormonal Regulation and Hypertension

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/hormonal-regulation-and-hypertension/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the management, diagnosis, and treatment of Primary Aldosteronism, a condition characterized by the overproduction of aldosterone by the adrenal glands. The research covers topics such as case detection, cardiovascular events, glucocorticoid and mineralocorticoid receptor actions, hypertension, and the use of spironolactone therapy. Additionally, it explores the association with metabolic syndrome and renal injury. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11839 |
| Works | 462 |

## Topic papers all

Showing 15 of 462.

- [The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure](https://scholariq.org/papers/the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients-with-severe/)
- [Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol](https://scholariq.org/papers/cardiovascular-morbidity-and-mortality-in-the-losartan-intervention-for-endpoint/)
- [Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction](https://scholariq.org/papers/eplerenone-a-selective-aldosterone-blocker-in-patients-with-left-ventricular/)
- [2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines](https://scholariq.org/papers/2017-acc-aha-aapa-abc-acpm-ags-apha-ash-aspc-nma-pcna-guideline-for-the-4/)
- [Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms](https://scholariq.org/papers/eplerenone-in-patients-with-systolic-heart-failure-and-mild-symptoms/)
- [Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension](https://scholariq.org/papers/randomised-double-blind-comparison-of-placebo-and-active-treatment-for-older/)
- [The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline](https://scholariq.org/papers/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment/)
- [Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline](https://scholariq.org/papers/pheochromocytoma-and-paraganglioma-an-endocrine-society-clinical-practice/)
- [Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes](https://scholariq.org/papers/effect-of-finerenone-on-chronic-kidney-disease-outcomes-in-type-2-diabetes/)
- [Spironolactone for Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/spironolactone-for-heart-failure-with-preserved-ejection-fraction/)
- [Resistant Hypertension: Diagnosis, Evaluation, and Treatment](https://scholariq.org/papers/resistant-hypertension-diagnosis-evaluation-and-treatment-2/)
- [Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19](https://scholariq.org/papers/renin-angiotensin-aldosterone-system-inhibitors-in-patients-with-covid-19/)
- [Calcitonin gene-related peptide is a potent vasodilator](https://scholariq.org/papers/calcitonin-gene-related-peptide-is-a-potent-vasodilator/)
- [Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients](https://scholariq.org/papers/benazepril-plus-amlodipine-or-hydrochlorothiazide-for-hypertension-in-high-risk/)
- [Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)](https://scholariq.org/papers/morbidity-and-mortality-in-the-swedish-trial-in-old-patients-with-hypertension/)

## Topic primary papers

Showing 15 of 192.

- [The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure](https://scholariq.org/papers/the-effect-of-spironolactone-on-morbidity-and-mortality-in-patients-with-severe/)
- [Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction](https://scholariq.org/papers/eplerenone-a-selective-aldosterone-blocker-in-patients-with-left-ventricular/)
- [Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms](https://scholariq.org/papers/eplerenone-in-patients-with-systolic-heart-failure-and-mild-symptoms/)
- [The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline](https://scholariq.org/papers/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment/)
- [Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes](https://scholariq.org/papers/effect-of-finerenone-on-chronic-kidney-disease-outcomes-in-type-2-diabetes/)
- [Spironolactone for Heart Failure with Preserved Ejection Fraction](https://scholariq.org/papers/spironolactone-for-heart-failure-with-preserved-ejection-fraction/)
- [Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19](https://scholariq.org/papers/renin-angiotensin-aldosterone-system-inhibitors-in-patients-with-covid-19/)
- [Molecular Mechanisms of Human Hypertension](https://scholariq.org/papers/molecular-mechanisms-of-human-hypertension/)
- [A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients](https://scholariq.org/papers/a-prospective-study-of-the-prevalence-of-primary-aldosteronism-in-1-125/)
- [Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial](https://scholariq.org/papers/spironolactone-versus-placebo-bisoprolol-and-doxazosin-to-determine-the-optimal/)
- [LOCALISATION OF 11β-HYDROXYSTEROID DEHYDROGENASE—TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTOR](https://scholariq.org/papers/localisation-of-11-hydroxysteroid-dehydrogenase-tissue-specific-protector-of-the/)
- [11β-Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response](https://scholariq.org/papers/11-hydroxysteroid-dehydrogenase-type-1-a-tissue-specific-regulator-of/)
- [Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction](https://scholariq.org/papers/finerenone-in-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/)
- [Does central obesity reflect “Cushing's disease of the omentum”?](https://scholariq.org/papers/does-central-obesity-reflect-cushing-s-disease-of-the-omentum/)
- [Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy](https://scholariq.org/papers/effect-of-finerenone-on-albuminuria-in-patients-with-diabetic-nephropathy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.